Publications by authors named "E STEIN"
Background: Lerodalcibep, a small binding anti-PCSK9 protein (adnectin), showed effective LDL cholesterol reduction in heterozygous familial hypercholesterolaemia. We aimed to assess the safety and efficacy of lerodalcibep and evolocumab in a globally diverse homozygous familial hypercholesterolaemia population.
Methods: This phase 3, randomised, open-label, crossover, non-inferiority study consisted of two 24-week treatment periods separated by an 8-week washout.
Article Synopsis
- This study focuses on PRT543, a new oral medication designed to inhibit PRMT5, an enzyme implicated in the growth of certain blood cancers.
- It specifically investigates the effects of PRT543 in patients suffering from advanced myeloid malignancies that have mutations in splicing factors, which are crucial for proper gene expression and can contribute to cancer progression.
- The early Phase Ib trial aims to assess the safety, tolerability, and initial effectiveness of PRT543 in these patients, providing groundwork for potential future treatments.
Intravascular Imaging as a Performance Measure for Percutaneous Coronary Intervention.
Circ Cardiovasc Interv
January 2025
Background: Intravascular imaging (IVI) is widely recognized to improve outcomes after percutaneous coronary intervention (PCI). However, IVI is underutilized and is not yet established as a performance measure for quality PCI.
Methods: We examined temporal trends of IVI use for all PCIs performed at Veterans Affairs hospitals in the United States from 2010 to 2022 using retrospective observational cohorts.
Background: The microbiome has been identified as a contributor to bone quality. As skeletal health is critical to success of orthopedic surgery, the gut microbiome may be a modifiable factor associated with postoperative outcomes. For spine fusion surgery in particular, bone formation and sufficient bone mineral density are essential for successful outcomes.
View Article and Find Full Text PDFThe 24 Annual Santa Fe Bone Symposium (SFBS) was held in Santa Fe, New Mexico, USA, on August 2-3, 2024. This was a "hybrid" meeting, with in-person and real-time remote participants representing a broad range of geographical locations and medical disciplines. The focus was on new developments in the care of patients with osteoporosis, other metabolic bone diseases, and inherited skeletal disorders.
View Article and Find Full Text PDF